Skip to main content

Drug Interactions between pralsetinib and repotrectinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

pralsetinib repotrectinib

Applies to: pralsetinib and repotrectinib

Repotrectinib may significantly reduce the blood levels of pralsetinib, which may make the medication less effective in treating your cancer. Your doctor(s) may be able to prescribe alternatives that do not interact. However, they may already be aware of the risks, but determined that this is the best course of treatment for you and have taken appropriate precautions, such as adjusting the dose of pralsetinib and/or monitoring you closely for any potential complications. Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you experience side effects such as fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, light colored stools, or yellowing of the skin or eyes during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Drug and food interactions

Major

pralsetinib food

Applies to: pralsetinib

Food should not be consumed for at least 2 hours before and at least 1 hour after taking pralsetinib. Do not consume grapefruit, grapefruit juice, any supplements that contain grapefruit, Seville oranges, or Seville orange juice as these products can increase the blood levels of pralsetinib. This may increase the risk and/or severity of serious side effects such as lung problems, liver problems, high blood pressure, fatigue, muscle and joint pain, and bleeding complications. Some sources also warn that combining these medicines could increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac disease, conduction abnormalities, or electrolyte disturbance (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Major

repotrectinib food

Applies to: repotrectinib

Consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit should be avoided during treatment with repotrectinib as they may increase the blood levels of repotrectinib. This may increase the risk and/or severity of side effects such as dizziness, tiredness, muscle pain, nausea, change in your sense of taste, feeling numbness or tingling in your arms or legs, constipation, trouble with balance, shortness of breath, problems with thinking such as forgetfulness or confusion and hallucinations, as well as more serious side effects such severe or life-threatening inflammation of the lungs and liver injury. Talk to your doctor if you have any questions or concerns. Your doctor may be able to provide alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Multikinase inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:

  • pralsetinib
  • repotrectinib

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer